- Home
- EPOW vs CMMB Comparison
EPOW vs CMMB Comparison
Compare EPOW & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPOW
- CMMB
- Stock Information
- Founded
- EPOW 2014
- CMMB 2004
- Country
- EPOW China
- CMMB Israel
- Employees
- EPOW N/A
- CMMB N/A
- Industry
- EPOW Business Services
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- EPOW Consumer Discretionary
- CMMB Health Care
- Exchange
- EPOW Nasdaq
- CMMB Nasdaq
- Market Cap
- EPOW 24.1M
- CMMB 22.0M
- IPO Year
- EPOW 2021
- CMMB N/A
- Fundamental
- Price
- EPOW $0.88
- CMMB $3.05
- Analyst Decision
- EPOW
- CMMB Strong Buy
- Analyst Count
- EPOW 0
- CMMB 2
- Target Price
- EPOW N/A
- CMMB $26.50
- AVG Volume (30 Days)
- EPOW 14.6K
- CMMB 139.0K
- Earning Date
- EPOW 05-15-2025
- CMMB 08-14-2025
- Dividend Yield
- EPOW N/A
- CMMB N/A
- EPS Growth
- EPOW N/A
- CMMB N/A
- EPS
- EPOW N/A
- CMMB N/A
- Revenue
- EPOW $64,997,741.00
- CMMB N/A
- Revenue This Year
- EPOW N/A
- CMMB N/A
- Revenue Next Year
- EPOW N/A
- CMMB N/A
- P/E Ratio
- EPOW N/A
- CMMB N/A
- Revenue Growth
- EPOW 44.28
- CMMB N/A
- 52 Week Low
- EPOW $0.70
- CMMB $2.98
- 52 Week High
- EPOW $1.36
- CMMB $9.84
- Technical
- Relative Strength Index (RSI)
- EPOW 44.96
- CMMB 23.54
- Support Level
- EPOW $0.86
- CMMB $2.99
- Resistance Level
- EPOW $1.00
- CMMB $3.86
- Average True Range (ATR)
- EPOW 0.03
- CMMB 0.27
- MACD
- EPOW -0.00
- CMMB -0.02
- Stochastic Oscillator
- EPOW 17.93
- CMMB 5.70
About EPOW Sunrise New Energy Co. Ltd
Sunrise New Energy Co Ltd is engaged in the manufacturing and sale of graphite anode material for EVs and other lithium-ion batteries. The Company's joint venture is in the construction of a manufacturing plant in Guizhou Province. The plant runs on inexpensive electricity from renewable sources that enables the group to be a low-cost and low environmental impact producer of graphite anode material, Its products include GS-1, GS-2, GS-3, GZD-1, GLD-1, and GZ-1.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.